The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified. Study author Melinda J.

Safety 36

Safety Eczema Social Media Dermatology 36

Dermatology Times

JUNE 4, 2024

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Safety 69

Safety Therapy Dermatology 69

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Safety 77

The Dermatology Digest

SEPTEMBER 9, 2024

In a preliminary review by an independent data safety committee, the ongoing study of 60 patients demonstrated a much lower incidence and severity of side effects as well as improved efficacy for preventing Raynaud’s attacks, when compared to published reviews of current therapies.

Portfolios 36

Portfolios Dermatology Injections Innovations 36

The Dermatology Digest

AUGUST 30, 2024

The safety profile of pembrolizumab in this trial was consistent with the drug’s established safety profile. The primary endpoint is RFS, and key secondary endpoints include OS and safety. The post Keytruda Disappoints in Phase III SCC Trial; Merck Halts Study appeared first on The Dermatology Digest.

Surgery 36

Surgery Safety Therapy Innovations 36

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Safety 74

Safety Dermatology Clinic Therapy 74

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

FEBRUARY 16, 2024

One of the biggest challenges in CAR T-cell therapies is the scarcity of suitable tumor targets,” says study author Cristina Puig-Saus, PhD, assistant professor of medicine at the David Geffen School of Medicine at UCLA, in a news release. “One

Therapy 36

Therapy Clinic Safety Treatments 36

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

Dermatology Times

MARCH 14, 2024

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Management 74

Management Safety Therapy Treatments 74

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Dermatology Injections 36

The Dermatology Digest

APRIL 4, 2024

The safety profile of Bimzelx was consistent with previous studies with no new safety signals observed. in October 2023 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In addition, improvements increased for patients in these studies over 48 weeks.

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

JUNE 14, 2024

ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile. ICP-332 showed better efficacy profile across different classes and mechanisms of action of therapies for the treatment of AD patients although this was not a head-to-head study.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

MAY 22, 2024

The BLA is seeking approval of subcutaneous nivolumab across all previously approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy , BMS ) combination therapy, or in combination with chemotherapy or cabozantinib.

Safety 36

Safety Therapy Dermatology 36

The Dermatology Digest

JULY 10, 2024

The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

The Dermatology Digest

AUGUST 14, 2024

Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study. The post Topline Results: Verrica’s VP-315 Performs Well in BCC Trial appeared first on The Dermatology Digest.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

MAY 22, 2024

The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. In this 5-arm trial, approximately 250 patients will receive topical therapy for 16 weeks.

Clinic 36

Clinic Therapy Safety Treatments 36

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

APRIL 17, 2024

The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CIndU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

MARCH 9, 2024

Apremilast (Otzela, Amgen) can improve symptoms in patients with moderate to severe palmoplantar pustulosis who had an inadequate response to topical therapy, according to a late-breaking Phase 3 study presented at the annual meeting of the American Academy of Dermatology in San Diego, CA.

Safety 36

Safety Dermatology Therapy Clinic 36

The Dermatology Digest

JULY 22, 2024

In January 2024, Uzpruvo became the first ustekinumab biosimilar to be approved by the European Commission as having equivalent efficacy, safety, pharmacokinetics and immunogenicity to the Stelara reference product.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 14, 2023

The study included 30 patients with ≥3% BSA who have been on stable biologic therapy for at least 26 weeks. Patients returned at week 16 to assess safety and evaluate maintenance response. ” Moreover, Vtama cream was well tolerated, with no new safety signals when used in combination with injectable biologics.

Injections 36

Injections Safety Office Therapy 36

The Dermatology Digest

FEBRUARY 7, 2024

IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe plaque psoriasis (PsO) and underpins the inflammatory response in PsO and other dermatological and gastroenterological IL-23-mediated diseases. JNJ-2113 is the first and only investigational targeted oral peptide inhibitor designed to block the IL-23 receptor.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

FEBRUARY 6, 2024

The sNDA is supported by two clinical phase I studies investigating the safety of the application of three tubes of Ameluz. Further to a Type A meeting with the FDA in 2021, an additional safety trial with 100 patients receiving PDT with three tubes of Ameluz was conducted.

Safety 28

Safety Office Therapy Ingredients 28

The Dermatology Digest

MARCH 11, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Recommend proactive therapy with topical corticosteroids or topical calcineurin inhibitors for patients with a relapsing course of AD. Urge consideration for once-daily dosing of topical medications.

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

The Dermatology Digest

FEBRUARY 13, 2024

EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds that is currently in the advanced stages of clinical development. The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0 days for Santyl.

Safety 36

Safety Marketing Office Clinic 36

The Dermatology Digest

JANUARY 10, 2024

The trial was a 16-week open-label study assessing the safety, tolerability, pharmacokinetics, and exploratory efficacy of once-daily topical VYN201 in 29 patients with a clinical diagnosis of active nonsegmental vitiligo, in three dose cohorts (0.5%, 1.0% Positive clinical data from the Phase 1b trial were announced in October 2023.

Clinic 36

Clinic Safety Dermatology Treatments 36